Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

J&J submits EUL application to WHO for single-shot COVID-19 vaccine

By Sean Whooley | February 19, 2021

Johnson & JohnsonJohnson & Johnson (NYSE:JNJ) announced today that it submitted for emergency use listing (EUL) to the World Health Organization (WHO) for its COVID-19 vaccine.

New Brunswick, N.J.-based J&J’s Janssen subsidiary’s single-dose COVID-19 vaccine candidate was submitted for EUL with a data package including interim efficacy and safety results from the Phase 3 Ensemble clinical trial, which met all of its primary and key secondary endpoints, according to a news release.

EUL submission is a step forward in the process for a new or unlicensed product to be assessed for use during public health emergencies by governments and UN procurement agencies. Such listing would offer the single-dose vaccine in many countries and is a prerequisite to supply vaccines to the new COVAX Facility for pooled procurement and distribution of COVID-19 vaccines in 190 participating countries, including 92 lower-income countries.

Previously, J&J agreed in principle with Gavi, the Vaccine Alliance, to support the COVAX Facility, with plans to enter into an advance purchase agreement for up to 500 million doses of the vaccine to be provided to COVAX through 2022.

“Our filing with the World Health Organization marks another important step in our effort to combat COVID-19 and also in our unwavering commitment to equitable access,” J&J vice chairman & chief scientific officer Dr. Paul Stoffels said in the release. “If we are to end the global pandemic, life-saving innovations like vaccines must be within reach for all countries.”

Earlier this week, J&J submitted a conditional marketing authorization application (cMAA) with the European Medicines Agency (EMA) for its COVID-19 vaccine, having initiated a rolling submission with the EMA to enable the EMA to review data as it becomes available in December.

Additionally, the company earlier this month applied for FDA emergency use authorization (EUA) in the U.S., with a meeting of the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) scheduled for Feb. 26, 2021, to discuss the EUA request.

In previous announcements, J&J has said it expects to have product available to ship immediately following authorization. The company set its target to produce 1 billion doses in 2021 and expand production after that. The company has committed to not-for-profit pricing during the pandemic assuming its single-dose vaccine is authorized by FDA and other regulators. J&J is also investigating a two-dose regimen for its vaccine.


Filed Under: clinical trials, Drug Delivery, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, Covax, covid-19, COVID-19 vaccine, Janssen, Johnson & Johnson, WHO
 

About The Author

Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE